(Its worth noting that the committee was heavily made up of pro-peptide individuals, including doctors, and its also worth noting that the FDA itself advised against loosening restrictions, saying theres just not enough clinical evidence yet.) Approved peptides are thus eligible to be moved to the Section 503A Bulk List, which means compounding pharmacies could legally prepare said peptides for patientswith a valid prescription and specific quality and testing standards
High total glutathione is associated with chemotherapy resistance (Traverso 2013), dyserythropoietic disorders (Kobayashi 2022), WBCs above 20x10(9)/L (which can falsely elevate glutathione levels by 25%), myelofibrosis, pyrimidine 5-nucleotidase deficiency, and riboflavin supplementation (Mayo Clinic)
Symptoms include persistent redness, new breakouts, and skin sensitivity that worsens over time instead of improving
For the scenario of "Cognitive Enhancement Research," research data suggests Dihexa may be more relevant
The damage happens in deep sleep: alcohol cuts slow-wave sleep, and slow-wave sleep is when the biggest growth hormone pulse of the day occurs
Electronic Code of Federal Regulations: 21 CFR 216.23 Current formal 503A Bulks List and the regulatory warning that list inclusion is not FDA approval or endorsement